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Summary
Background.— Screening for silent myocardial ischaemia (SMI) is a controversial strategy under-
going intensive risk factor therapy.
Aims.— To assess the prevalence of SMI and coronary artery disease (CAD) in asymptomatic
type 2 diabetic patients at high cardiovascular risk (two additional risk factors or more) andDiabetes mellitus;
Prevention;
Silent myocardial
ischaemia
undergoing long-term intensive risk factor therapy and tight glycaemic control.
Methods.— SMI screening, using isotopic or echographic stress tests, was carried out in 122
asymptomatic type 2 diabetic patients at high cardiovascular risk and undergoing long-term
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Conclusion.— Le traitement intensif et prolongé des facteurs de risque cardiovasculaire du
diabétique de type 2 est associé à une faible prévalence d’IMS, de maladie coronaire dépistée.
Un traitement médical optimal avec revascularisation des sténoses signiﬁcatives est associé à
ment
. All
A
A
B
C
D
D
E
H
H
L
L
S
S
S
S
9
I
T
w
t
p
dun taux très faible d’événe
© 2008 Elsevier Masson SAS
bbreviations
LFEDIAM Association de langue franc¸aise pour l’étude du
diabète et des maladies métaboliques
ARI 2D Bypass angioplasty revascularization investigation
2 diabetes
AD Coronary artery disease
E Dobutamine echocardiography
IAD Detection of ischemia in asymptomatic diabetics
CG Electrocardiogram
bA1c Glycosylated hemoglobin
DL High-density lipoprotein
DL Low-density lipoprotein
VEF Left ventricular ejection fraction
.D. Standard deviation
FC Société franc¸aise de cardiologie
A
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MI Silent myocardial ischaemia
PECT Single photon emission computed tomography
9mTc-sestamibi Technetium-99m-methoxyisobutyl isoni-
trile
ntroduction
he prevalence of type 2 diabetes mellitus is increasing
orldwide [1]. Cardiovascular events, often atypical in fea-
ure, are the main cause of death in this population. The
revalence of SMI is higher in these patients than in non-
iabetic patients and has a poorer prognosis [2].O. Barthelemy et al.
intensive risk factor therapy. Coronary angiography was proposed if SMI was detected. Long-
term follow-up data on death, myocardial infarction and revascularization were obtained by
telephone call or clinical review.
Results.— The mean age was 65± 6 years and 74% of patients were men. The mean duration of
diabetes was 15± 9 years. The mean number of additional risk factors was 2.9, 32% of patients
had microalbuminuria and 12% had peripheral arterial disease. SMI was detected in 20 (16%)
patients. Seven (6%) patients had signiﬁcant CAD treated successfully by angioplasty (n = 6) or
bypass surgery (n = 1). The positive predictive value of the non-invasive screening test for the
diagnosis of signiﬁcant CAD (stenosis > 50%) was 39%. The event rate was very low (1.6%) at
2-year follow-up.
Conclusion.— Long-term intensive risk factor therapy in high-risk patients with type 2 dia-
betes is associated with low prevalence of SMI and detected CAD. Optimal medical therapy and
revascularization of signiﬁcant CAD are associated with a low cardiovascular event rate at two
years.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Objectif.— Étude de la prévalence de l’ischémie myocardique silencieuse (IMS) et de la maladie
coronaire chez le patient diabétique de type 2 à haut risque cardiovasculaire (supérieur ou égal
à deux facteurs de risque [FdR] supplémentaires) avec prise en charge intensive des facteurs
de risque et un contrôle glycémique optimal.
Méthodes.— Cent vingt-deux patients diabétiques de type 2 asymptomatiques à haut risque car-
diovasculaire et bénéﬁciant d’un traitement intensif au long court des FdR cardiovasculaires ont
bénéﬁcié d’un dépistage de l’IMS. Le test de dépistage était soit une scintigraphie myocardique,
soit une échocardiographie de stress. En cas d’IMS, une coronarographie était proposée. Le suivi
à long terme (mortalité, infarctus, revascularisation) était effectué par contact téléphonique
ou au cours de consultation.
Résultats.— L’âge moyen était de 65± 6 ans, le sexe masculin était prédominant (74 %).
L’ancienneté du diabète était de 15± 9 ans. Le nombre de FdR associé était de 2,9 (TA moyenne
133/73, LDL cholestérol 1,0 g/l), 32 % avait une microalbuminurie et 12 % une artériopathie
des membres inférieurs. Une IMS a été dépisté chez 20 patients (16 %). Sept patients (6 %)
avaient une maladie coronaire signiﬁcative traitée avec succès par angioplastie (n = 6) ou pon-
tage (n = 1). La valeur prédictive positive des tests non invasifs de dépistage pour le diagnostic
de maladie coronaire (sténoses > 50%) était de 39%. Le taux d’événements était très bas (1,6 %),
après un suivi moyen de 24± 10 mois.To prevent adverse cardiovascular events, the SFC/
LFEDIAM and the American College of Cardiology/American
iabetes Association (ACC/ADA) have provided guidelines
or the detection of asymptomatic CAD in patients with type
diabetes [3,4].
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Despite a number of trials involving patients with type
2 diabetes, the usefulness of SMI screening remains con-
troversial, especially in the context of intensive risk factor
therapy [5]. The need for systematic preoperative coronary
angiography and revascularization in high-risk patients is
also inconclusive [6,7]. Moreover, several studies have failed
to show any prognostic beneﬁt of systematic revascular-
ization for stable CAD [8,9]. Whether these results can be
extrapolated to patients with type 2 diabetes is unknown,
although the ongoing Bypass angioplasty revascularization
investigation 2 diabetes (BARI 2D) trial may bring some
answers [10].
The aim of our study was to assess the prevalence of SMI
and CAD in patients with type 2 diabetes selected according
to SFC/ALFEDIAM guidelines in the setting of intensive risk
factor therapy and tight glycaemic control.
Patients and methods
Patients
One hundred and forty-six patients with type 2 diabetes mel-
litus were included prospectively between November 2003
and October 2006. The screening was performed in consul-
tation in the Department of Diabetology. The population
comprised consecutive patients selected for their high-risk
proﬁle according to speciﬁc inclusion and exclusion crite-
ria (Table 1). All patients had been receiving long-term
intensive treatment of atherosclerotic risk factors since
2001, with stepwise implementation of behaviour modiﬁca-
tion and pharmacological therapy targeting hyperglycaemia,
hypertension and dyslipidaemia [11]. The treatment objec-
tives were glycosylated haemoglobin (HbA1c) less than 6.5%,
i
t
5
b
a
Table 1 Inclusion and exclusion criteria.
Inclusion criteria
Type 2 diabetes
> 60 years (men), > 55 years (women)
No clinical symptoms of CAD
AND peripheral or carotid occlusive arterial disease
OR microalbuminuria (> 300mg/day)
OR abnormal ECG (repolarization change, bundle branch b
OR heart failure (LVEF <40%)
OR≥2 of the following risk factors:
High blood pressure, deﬁned as systolic blood pressure≥
≥ 2 occasions, or antihypertensive therapy
Dyslipidaemia, deﬁned as plasma concentration of LDL c
triglycerides > 1.5 g/L, or lipid-lowering therapy
Obesity (body mass index > 30 kg/m2)
Family history of premature CAD
Active smoker (> 10 cigarettes per day)
Retinopathy (panphotocoagulated)
Exclusion criteria
Symptoms of CAD
History of CAD (previous myocardial revascularization, cor
Acute coronary syndrome
CAD: coronary artery disease; ECG: electrocardiogram; LDL: low-density
ejection fraction541
lood pressure less than 130/80mmHg, and LDL cholesterol
lasma concentration less than 1 g/L. Daily life activity and
moking cessation were encouraged strongly.
Diabetes was diagnosed according to WHO criteria
12]. Latent autoimmune diabetes and secondary diabetes
ere ruled out for all patients. Associated cardiovas-
ular risk factors were deﬁned as follows: age over
5 years for men and over 60 years for women, obe-
ity (body mass index > 30 kg/m2), high blood pressure
systolic > 140mmHg and/or diastolic > 80mmHg), dyslipi-
aemia (LDL cholesterol > 1.3 g/L, HDL cholesterol < 0.35 g/L
r triglycerides > 1.5 g/L), active smoker, and family his-
ory of premature CAD (< 55 years for men, < 60 years
or women). All patients underwent evaluation of dia-
etes complications, including fundoscopy, measurement of
icroalbuminuria and proteinuria during a 24-hour urine col-
ection and ultrasound visualization/examination of periph-
ral arteries. Microangiopathy was deﬁned as the presence
f panphotocoagulated retinopathy and/or microalbumin-
ria (> 300mg/day). All patients gave informed consent and
he study was approved by the local institutional ethics com-
ittee.
tudy design
atients underwent stress thallium-201 SPECT or DE. Treat-
ent with nitrates, betablockers and calcium channel
lockers was stopped more than or equal to 48 h before
he tests. Coronary angiography was offered to all patients
f myocardial ischaemia was detected by a non-invasive
est. All patients with signiﬁcant CAD (greater or equal to
0% stenosis in greater or equal to one major vessel or
ranch) suitable for revascularization were treated system-
tically with angioplasty or surgery as appropriate. Aspirin
lock)
140mmHg or diastolic blood pressure ≥ 80mmHg on
holesterol > 1.3 g/L, HDL cholesterol < 0.35 g/L,
onary angioplasty or surgery)
lipoprotein; HDL: high-density lipoprotein; LVEF: Left ventricular
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100mg/day) was given to all patients except those with a
ormal coronary angiography, and betablockers were given
o all patients with myocardial ischaemia and CAD. Long-
erm follow-up data were obtained by clinical review or
egular telephone interviews. Clinical events were corrobo-
ated by primary source documentation.
on-invasive stress test
yocardial perfusion imaging
symptom-limited exercise protocol was performed on
cycloergometer, associated with dipyridamole infusion
0.7mg/kg over 4min) if the expected maximum heart rate
chievable by the patient was less than 85% of the predicted
aximum heart rate. 99mTc-sestamibi was injected at peak
xercise.
ECG-gated SPECT was performed using a two-day pro-
ocol. Acquisition was performed 45min (stress) or 60min
rest) after infusion of 11MBq/kg 99mTc-sestamibi on a DST-
Li dual-head gamma camera (GEMS, Buc, France) equipped
ith low-energy high-resolution parallel collimators. Data
ere acquired on a 64× 64 matrix for 32 projections
50 s/projection), with 16 frames/cycle.
All acquisitions were reviewed by two experienced
uclear cardiologists for assessment of myocardial perfusion
efects. The extent of the defects was quantiﬁed on a 17-
egment model and their severity was graded on a 5-point
cale ranging from 0 (normal) to 4 (no uptake). A test was
onsidered to be abnormal if the summed stress score was
reater than 3 [13,14].
E
standard echocardiographic evaluation with tissue har-
onic imaging (ACUSON Sequoia C256, Siemens Medical
olutions USA, Inc., Malvern, PA, USA) was carried out for
ll patients. A stress DE test was performed using a standard
ncremental dosing protocol from 5—40g/kg per minute
ntravenously [15]. As the last dose was given, an intra-
enous bolus of atropine 0.25mg (up to 1mg) was added
o achieve maximum heart rate. Heart rate and rhythm
ere monitored continuously and blood pressure and a
2-lead ECG were recorded every 3min. Symptoms were
ocumented.
Images were digitized online into a quad-screen display,
nd were interpreted by an experienced observer trained in
he technique. Analyses were performed in the four standard
maging planes: parasternal long-axis, parasternal short-
xis, apical four-chamber and apical two-chamber views
16]. Segmental wall motion was assessed with a 16-segment
odel and graded visually as normal, hypokinetic, akinetic,
r dyskinetic. Myocardial ischaemia was identiﬁed in the
resence of a new or worsening wall motion abnormality
n two or more contiguous segments.
oronary angiogramatients with SMI underwent coronary angiography within
ne week of isotopic or echocardiographic testing.
fter intracoronary injection of linsidomine 1mg, digi-
al computer-assisted calipers (DCI, Philips Healthcare,
ndover, MA, USA) were used to measure stenotic seg-
S
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ents of the arteries in the view showing the most severe
ross-sectional narrowing. Coronary arteries were consid-
red to be angiographically normal (without irregularities),
nobstructed (< 25% diameter stenosis) or obstructed (> 50%
iameter stenosis in a segment with a normal diameter
1.5mm) [17].
ollow-up
ollow-up focused on the incidence of death, myocardial
nfarction and revascularization. In patients who had under-
one coronary angioplasty, stress SPECT was performed
ystematically six months after the procedure. A new coro-
ary angiogram was performed in patients who experienced
ccurrence of clinical symptoms during follow-up or in whom
tress SPECT demonstrated ischaemia that was either severe
r involved new segments. Restenosis was diagnosed when
narrowing of more than 50% of vessel diameter was found
t the site of the previous dilatation. Clinical restenosis was
eﬁned as recurrent myocardial ischaemia related to angio-
raphic restenosis. Indications for a new revascularization
rocedure were either the appearance of a new signiﬁcant
oronary artery stenosis not present on the initial angiogram
r restenosis at a site of the previous dilatation.
tatistical analysis
ontinuous variables are presented as mean and standard
eviation (S.D.). Categorical data are presented as numbers
nd percentages. Univariate analyses were performed using
he chi-square test for categorical data and analysis of vari-
nce for continuous variables. A multivariable analysis was
erformed using a multiple regression model including all
nivariate variables with a p-value < 0.1.
esults
f the 146 patients included in the study, 122 achieved an
nalysable stress test. Fifty-nine patients underwent DE and
3 underwent SPECT. Eighteen patients refused to partici-
ate in a stress test. Adequate DE could not be performed
n six patients: three with poor echogenicity, two with aortic
tenosis and one with high pretest blood pressure.
linical characteristics
he mean age of the study population was 65 years and most
atients (74%) were men. The mean duration of diabetes was
5 years, 40% of patients were treated with insulin and 60%
eceived oral antidiabetic therapy alone. The study popu-
ation was at high cardiovascular risk with a mean of 2.9
dditional conventional risk factors; 32% had microalbumin-
ria and 12% had peripheral arterial disease. Only 15% of
atients had an abnormal ECG.
revalence of SMI and detected CADMI was detected by SPECT or DE in 20 (16%) patients.
f the 63 patients who underwent SPECT, 12 (19%) had
MI. The mean maximum predicted heart rate achieved
as 86%. The stress test took the form of exercise in
Intensive care of cardiovascular risk factors 543
Table 2 Univariate comparison of baseline characteristics between patients with or without silent myocardial ischemia.
Patients with SMI (n = 20) Patients without SMI (n = 102) p
Mean age± S.D., years 64± 6 65± 6 ns
Men, n (%) 16 (80) 74 (73) ns
Mean risk factors± S.D., n 2.8± 1.0 2.9± 0.8 ns
Mean body mass index± S.D., kg/m2 30± 7 29± 5 ns
High blood pressure, n (%) 18 (90) 91 (89) ns
Dyslipidaemia, n (%) 14(70) 81 (79) ns
Mean total cholesterol± S.D., g/L 1.8± 0.6 1.8± 0.4 ns
Mean LDL cholesterol± S.D., g/L 1.0± 0.5 1.0± 0.3 ns
Mean HDL cholesterol± S.D., g/L 0.6± 0.2 0.5± 0.1 0.08
Mean triglyceride± S.D., g/L 1.5± 1.7 1.4± 0.9 ns
Active smoker, n (%) 2 (10) 18 (18) ns
Family history of premature CAD, n (%) 2 (10) 4 (4) ns
Peripheral/carotid arterial disease, n (%) 6 (30) 13 (13) 0.08
Microangiopathy, n (%) 6 (30) 38 (37) ns
Microalbuminuria, n (%) 4 (20) 35 (34) ns
Retinopathy (panphotocoagulated), n (%) 3 (15) 13 (11) ns
Abnormal ECG, n (%) 5 (25) 13 (13) ns
Mean duration of diabetes± S.D., years 20± 11 14± 9 0.004
Mean fasting plasma glucose± S.D., mmol/l 8.5± 2.4 8.4± 2.0 ns
Mean HbA1c± S.D., % 7.8± 1.5 7.6± 1.6 ns
Insulin, n (%) 11 (55) 38 (37) ns
Oral antidiabetic, n (%) 17 (85) 89 (87) ns
Betablocker, n (%) 5 (25) 18 (18) ns
Angiotensin-converting enzyme inhibitor, n (%) 12 (60) 40 (39) ns
Angiotensin II receptor antagonist, n (%) 6 (30) 43 (42) ns
Antiplatelet therapy, n (%) 14 (70) 48 (47) 0.09
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49% of patients, intravenous infusion of dipyridamole in
10% of patients, and a combination in 41% of patients. Of
the 59 patients who underwent DE, eight (14%) had SMI.
Two patients had intraventricular gradient, one patient had
a non-sustained ventricular tachycardia and one patient
had transient atrial ﬁbrillation during dobutamine infusion.
Three patients did not reach 85% of the maximum predicted
heart rate despite having received the highest doses of dobu-
tamine and atropine. The mean maximum predicted heart
rate achieved was 92%, with a mean of 24g/kg per minute
of dobutamine plus 0.75mg of atropine.
Table 2 shows the baseline characteristics of the patients
according to the presence or absence of SMI. In the univari-
ate analysis, only the duration of diabetes was associated
signiﬁcantly with SMI. The multivariable analysis, which
included all variables with a p-value < 0.1 on univariate anal-
ysis, indicated that the duration of diabetes was the only
independent predictor of SMI (p = 0.02).
Two of the 20 patients with SMI declined coronary angiog-
raphy. In the remaining 18 patients coronary angiography
revealed signiﬁcant coronary stenoses in seven patients,
non-signiﬁcant lesions in four patients, and was normal in
seven patients. Thus, the positive predictive value of the
non-invasive stress test (SPECT or DE) to detect signiﬁcant
coronary stenosis was 39%. The seven patients with sig-
niﬁcant stenosis (three with single-vessel disease and four
with multivessel disease) were compared with the patients
without SMI (n = 102) or without signiﬁcant coronary steno-
D
O
t
rnsity lipoprotein; LDL: low-density lipoprotein; S.D.: standard
is evident on angiogram (n = 11). No independent predictor
as found on multivariable analysis.
ollow-up
he long-term intensive treatment of modiﬁable atheroscle-
otic risk factors was continued during clinical follow-up in
ll patients, according to current guidelines. Six patients
ith signiﬁcant coronary stenosis were treated by coro-
ary angioplasty with drug-eluting stents and one patient
nderwent coronary artery bypass graft surgery. Long-term
linical follow-up data were available in 121 (99%) patients.
nly two cardiovascular events occurred during follow-up.
ne patient with an initial negative stress DE test had
myocardial infarction. Another patient with an initial
egative stress DE test developed angina two years after
creening and beneﬁted from percutaneous coronary inter-
ention. One patient with a negative stress SPECT test died
rom cancer (non-cardiac death). Thus, the cardiovascular
vent rate was 1.6% at a mean follow-up duration of 24± 10
onths.iscussion
ur study has shown a 16% prevalence of SMI in a popula-
ion of high-risk patients with asymptomatic type 2 diabetes
eceiving long-term intensive treatment of cardiovascular
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isk factors. We found that SMI was associated with the
uration of diabetes. Only 6% of patients with SMI had signiﬁ-
ant CAD on angiogram; percutaneous coronary intervention
as the principal revascularization therapy for patients with
AD. The cardiovascular event rate was very low (1.6%) at
wo-year follow-up.
The prevalences of SMI and detected CAD in our study
re much lower than those reported previously in patients
eceiving conventional care for cardiovascular risk factors.
he prevalence of SMI in the asymptomatic type-2 diabetic
opulation has been investigated in a number of studies,
nd has been shown to be three to six times higher in this
etting than in non-diabetic patients [18]. The presence of
MI is strongly indicative of a poor prognosis [2,19]. The
FC/ALFEDIAM and the ADA/ACC have therefore produced
trict guidelines that recommend SMI screening for diabetic
atients with peripheral or carotid disease or two or more
dditional risk factors [3,4].
In diabetic patients, the reported prevalence of SMI
aries from 12 to 62%; this discrepancy can be explained
n part by differences in patient selection and choice of
tress test [20]. In the large Milan Study on Atherosclero-
is and Diabetes (MiSAD), in which 925 asymptomatic type
diabetic patients were enrolled, the prevalence of SMI
ssessed by stress ECG treadmill test was a low 12%, but
he screened population was at very low risk (there was no
equirement for additional risk factors for enrolment) [21].
ikewise, Janand-Delenne et al. reported an 18% prevalence
f SMI in patients with type 2 diabetes who had only one or
ore additional risk factors [22]. In a similar population,
osson et al. reported a 33% prevalence of SMI using SPECT
23]. When the current recommended inclusion criteria are
dhered to — as in our study — the prevalence of SMI is
ound to be much higher. Thus, Valensi et al. found a 30%
revalence of SMI using a triple modality screening in 132
atients with asymptomatic type 2 diabetes, and Vanzetto
t al. found a 37% prevalence of reversible SPECT defects
mong 158 patients [2,24]. Among diabetic patients with
eripheral vascular disease, the prevalence of SMI has been
ound to be as high as 57% [25]. More recently, the ongoing
IAD study showed a high 22% prevalence of SMI assessed
y SPECT in 522 asymptomatic diabetic patients, despite a
ow-risk proﬁle (only 60% of patients fulﬁlled the ADA/ACC
riteria) [26]. In our study, the 16% prevalence of SMI in
ntensively treated high-risk patients with asymptomatic
ype 2 diabetes is lower than that reported in previous stud-
es of patients receiving conventional risk factor care. These
esults emphasize the beneﬁt of intensive therapy in type 2
iabetes.
We have reported previously our ﬁrst experience of sys-
ematic SMI screening (SPECT±DE) of high-risk patients with
symptomatic type 2 diabetes [17]. At that time, cardiovas-
ular risk factors were treated less intensively. Compared
ith the 100 patients in our previous study, the 122 patients
n this study have beneﬁted from long-term intensive ther-
py with better control of cardiovascular risk factors (blood
ressure 133/73 vs 139/76mmHg, LDL cholesterol 1.0 vs
.2 g/L) and glycaemia (HbA1c 7.7% vs 9.4%). Despite the
igher cardiovascular risk proﬁle of patients in this study
older, 65 vs 61 years; a higher proportion of men, 74% vs
3%; a trend for a higher mean number of risk factors, 2.9
s 2.6), we found a lower frequency of SMI (16% vs 62%) and
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etected CAD (6% vs 25%) than in our earlier study. These
ndings suggest that strict glycaemic control and intensive
reatment of cardiovascular risk factors are associated with
ower prevalences of SMI and CAD in patients with asymp-
omatic type 2 diabetes at high risk of coronary disease.
owever, this is an observational comparison that was not
respeciﬁed.
We have reported a surprisingly low cardiovascular event
ate (0.8%/year) in this high-risk population, with no car-
iovascular death; this is well below the almost 3% per year
ate observed in the overall diabetic population [27], and
he greater than 40% incidence of coronary heart disease at
0 years reported in diabetic patients with multiple risk fac-
ors [28]. The mortality rate is also lower than the reported
.2% annual cardiovascular death rate in diabetic patients
ith three associated risk factors [29]. These observations
robably reﬂect the global improvement in care of diabetes
s emphasized in the European action on secondary preven-
ion through intervention to reduce events (EUROASPIRE)
urveys [30]. It is now well established that patients with
iabetes beneﬁt from intensive cardiovascular risk factor
revention, i.e. statins for LDL cholesterol less than 1 g/L,
ngiotensin-converting enzyme inhibitors or angiotensin II
eceptor antagonists for blood pressure < 130/80mmHg, and
ight glucose control (HbA1C < 6.5%) [11]. In our study,
o event occurred in the group with SMI in which, the
even patients (6%) with detected signiﬁcant CAD underwent
yocardial revascularization.
Systematic screening for SMI among high-risk patients
ith asymptomatic type 2 diabetes is a controversial strat-
gy. The higher prevalence of SMI in this group than in the
eneral population, and the poorer prognosis with which SMI
s associated, provide a strong case in favour of systematic
creening. Betablockers are effective in reducing ischaemia
uring daily life and cardiovascular adverse events [31]. In
he Asymptomatic cardiac ischemia pilot (ACIP) study, revas-
ularization led to an improvement in the event-free survival
ate in patients with asymptomatic diabetes [32]. Revascu-
arization before renal transplantation has also been shown
o reduce the occurrence of adverse cardiovascular events in
symptomatic diabetic patients with end-stage renal failure
33]. However, these trials involved small sample sizes, and
ere conducted several years ago, before the widespread
se of intensive risk factor therapy and tight glycaemic con-
rol according to recent guidelines. More recently, Faglia
t al. reported a signiﬁcant 26% risk reduction in adverse
ardiovascular events at 54 months in a screened group com-
ared with a non-screened group [34]. This study is the ﬁrst
albeit with a small sample size — to show a prognostic
eneﬁt of systematic screening, but the results need to be
onﬁrmed in a large study.
Some concerns have arisen about the usefulness of
evascularization for stable CAD [8,9]. The recent Clin-
cal outcomes utilizing revascularization and aggressive
rug evaluation (COURAGE) study showed that interven-
ional therapy with angioplasty was no more beneﬁcial
han ischaemia — or symptom-driven therapy in stable CAD
atients [35]. However, it must be emphasized that the pop-
lation was highly selected (only 7% of the initial population
ere randomized) and that one-third of the patients in the
roup who received optimal medical therapy alone under-
ent percutaneous revascularization during follow-up.
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Before vascular surgery, no reduction in cardiovascular
adverse event rate was observed after preoperative myocar-
dial revascularization in high-risk asymptomatic patients
(> 30% of whom had type 2 diabetes) [6,7]. Furthermore,
a cost analysis has reported a higher cost and a higher car-
diovascular event rate for the screening strategy compared
with an unconditional treatment strategy [5]. But it must be
stressed that statin allocation (statin therapy only when SMI
detected) was not integrated into standard prevention care
in type 2 diabetes in that analysis.
Our results are consistent with those of the Multifactorial
intervention and cardiovascular disease in patients with type
2 diabetes (STENO-2) study, in which 160 patients with type 2
diabetes and microalbuminuria were randomized to receive
conventional or intensive treatment of cardiovascular risk
factors. The mean duration of follow-up was 7.8 years [36].
The authors reported a 50% reduction in the cardiovascu-
lar event rate (cardiovascular death, non-fatal myocardial
infarction, coronary artery bypass grafting, percutaneous
coronary intervention, non-fatal stroke, amputation as a
result of ischaemia, or vascular surgery for peripheral
atherosclerotic artery disease) in the intensive risk-factor
treatment group compared with the conventional care
group. Thus, only ﬁve patients need to be treated intensively
during this period to prevent one major adverse cardiovas-
cular event.
In summary, among intensively treated patients with type
2 diabetes, we found that the prevalence of SMI was low
(16%), that 94% of patients had no detected CAD, and that
the cardiovascular event rate was less than 2% at a 2-year
follow-up. Long-term intensive cardiovascular risk factor
therapy and tight glycaemic control are associated with
low prevalences of SMI and detected CAD, and a very low
cardiovascular event rate when revascularization of signif-
icant CAD is added to optimal medical therapy. The low
rate of revascularization (6%) in this study underlines the
importance of the contribution that intensive risk-factor
treatment can make in the achievement of a good prognosis
for these patients.
The beneﬁt of detection and treatment of SMI in high-risk
diabetic patients will be conﬁrmed by randomized studies
that are currently ongoing, and which should bring some
clariﬁcation to the issue of SMI screening (the DIAD study)
and to the issue of revascularization (the BARI-2 study).
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